IL-1β and IL-6 in community-acquired pneumonia: Bacteremic pneumococcal pneumonia versusMycoplasma pneumoniae pneumonia
Interleukin-1β (IL-1β) and interleukin-6 (IL-6) levels in 20 patients with bacteremicStreptococcus pneumoniae community-acquired pneumonia (CAP) were compared with these cytokine levels in 20 patients withMycoplasma pneumoniae CAP. All 40 patients survived hospitalization and underwent a follow-up examination one month later. Serum IL-1β and IL-6 levels were determined by the enzyme immunoassay (EIA) method using commercial kits. In the acute phase of CAP, IL-6 levels were significantly higher in theS. pneumoniae group (p=0.014), while IL-1β levels were higher in theM. pneumoniae group (p=0.046). In the convalescence phase, the two cytokines were detected in a considerable number of patients in both groups. In this phase, only the level of IL-1β was significantly higher in theM. pneumoniae group than in theS. pneumoniae group (p=0.03). We conclude that the levels of IL-1β and IL-6 are different between patients withS. pneumoniae-CAP andM. pneumoniae-CAP during the acute phase. In the convalescence phase, cytokine levels remain high in some of the CAP patients, but a significant difference between the groups exists only for IL-1β. Further studies are required.
KeywordsPublic Health Enzyme Internal Medicine Infectious Disease Pneumonia
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
Bartlett, J. G., Mundy, L. M.
Community-acquired pneumonia. N. Engl. J. Med. 333 (1995) 1618–1624.CrossRefPubMedGoogle Scholar
Waage, A., Brandtzaeg, P., Halsteusen, A., Kierulf, P., Espevik, T.
The complex pattern of cytokines in serum from patients with meningococcal septic shock. J. Exp. Med. 169 (1989) 333–338.CrossRefPubMedGoogle Scholar
Tracey, K. J., Beutler, B., Lowry, S. F., Merryweather, J., Wolpe, S., Milsark, I. W., Hariri, R. J., Fahey III, T. J., Zentella, A., Albert, J. D., Shires, G. T., Cerami, A.
Shock and tissue injury induced by recombinant human cachectin. Science 234 (1986) 470–474.PubMedGoogle Scholar
Movat, H. Z., Cybulsky, M. I., Colditz, I. G., Chan, M. K., Dinarillo, C. A.
Acute inflammation in gram-negative infection: endotoxin, interleukin-1, tumor necrosis factor, and neutrophils. Fed. Proc. 46 (1987) 97–104.PubMedGoogle Scholar
Demling, R. H.
The role of mediators in human ARDS. J. Crit. Care 3 (1988) 56–72.CrossRefGoogle Scholar
Moussa, K., Michie, H., Cree, I. A., McCafferty, A. C., Winter, J. H., Dhillon, D. P., Stephens, S., Brown, R. A.
Phagocyte function and cytokine production in community acquired pneumonia. Thorax 49 (1994) 107–111.PubMedGoogle Scholar
Pinsky, M. R., Vincent, J. L., Deviere, J., Alegre, M., Kahn, R. J., Dupont, E.
Serum cytokine levels in human septic shock. Chest 103 (1993) 565–575.PubMedGoogle Scholar
Casey, L., Balk, R. A., Bone, R. C.
Plasma cytokine and endotoxin levels correlate with survival in patients with the sepsis syndrome. Ann. Intern. Med. 119 (1993) 771–778.PubMedGoogle Scholar
Hack, C. E., De Groot, E. R., Felt-Bersma, R. J., Nuijens, J. H., Strack Van Schijndel, R. J., Eerenberg-Belmer, A. J. M., Thijs, L. G., Aarden, L. A.
Increased plasma levels of interleukin-6 in sepsis. Blood 74 (1989) 1704–1710.PubMedGoogle Scholar
Lieberman, D., Schlaeffer, F., Boldur, I., Lieberman, D., Horowitz, S., Friedman, M. G., Leinonen, M., Horovitz, O., Manor, E., Porath, A.
Multiple pathogens in adult patients admitted with community-acquired pneumonia: a one year prospective study of 346 consecutive patients. Thorax 51 (1996) 179–184.PubMedGoogle Scholar
Knaus, W. A., Zimmerman, J. E., Wagner, D. P., Draper, E. A., Lawrence, D. E.
APACHE-acute physiology and chronic health evaluation: a physiologically based classification system. Crit. Care Med. 9 (1981) 591–597.PubMedGoogle Scholar
Calandra, T., Gerain, J., Heumann, D., Baumgartner, J. D., Glauser, M. P.
High circulating levels of interleukin-6 in patients with septic shock: evolution during sepsis, prognostic value, and interplay with other cytokines. Am. J. Med. 91 (1991) 23–29.CrossRefPubMedGoogle Scholar
Calandra, T., Baumgartner, J. D., Grau, G. E., Wu, M. M., Lambert, P. H., Schellenkens, J., Verhoef, J., Glauser, M. P.
Prognostic values of tumor necrosis factor/cachectin, interleukin-1, interferon-α and interferon-γ in the serum of patients with septic shock. J. Infect. Dis. 161 (1990) 982–987.PubMedGoogle Scholar
Damas, P., Reuter, A., Gysen, P., Demonty, J., Lamy, M., Franchimont, P.
Tumor necrosis factor and interleukin-1 serum levels during severe sepsis in humans. Crit. Care Med. 17 (1989) 975–978.PubMedGoogle Scholar
Helfgott, D. C., Tatter, S. B., Santhanam, U., Clarick, R. H., Bhardwaj, N., May, L. T., Sehgal, P. B.
Multiple forms of IFN-β2
/II-6 in serum and body fluids during acute bacterial infection. J. Immunol. 142 (1989) 948–953.PubMedGoogle Scholar
Waage, A., Halstensen, A., Espevik, T.
Association between tumor necrosis factor in serum and fatal outcome in patients with meningococcal disease. Lancet i (1987) 355–357.CrossRefGoogle Scholar
Marik, P., Kraus, P., Sribante, J., Havlik, I., Lipman, J., Johnson, D. W.
Hydrocortisone and tumor necrosis factor in severe community-acquired pneumonia. A randomized controlled study. Chest 104 (1993) 389–392.PubMedGoogle Scholar
Beutler, B., Krochin, N., Milsark, I. W., Luedke, C., Cerami, A.
Control of cachectin (tumor necrosis factor) synthesis: mechanisms of endotoxin resistance. Science 232 (1986) 977–980.PubMedGoogle Scholar
Sheppard, B. C., Fraker, D. L., Norton, J. A.
Prevention and treatment of endotoxin and sepsis lethality with recombinant tumor necrosis factor. Surgery 106 (1989) 156–162.PubMedGoogle Scholar
Preiser, J. C., Schmartz, D., Van der Linden, P., Content, J., Vanden Bussche, P., Buurman, W., Sebald, W., Dupont, E., Pinsky, M. R., Vincent, J. L.
Interleukin-6 administration has no acute hemodynamic or hematologic effect in the dog. Cytokine 3 (1991) 1–4.CrossRefPubMedGoogle Scholar
© MMV Medizin Verlag GmbH München 1997